A Study of NB003 in Patients With Advanced Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04936178 |
|
Recruitment Status :
Recruiting
First Posted : June 23, 2021
Last Update Posted : May 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumor | Drug: NB003 tablets | Phase 1 |
This is a phase 1, open-label, multicenter study of NB003 which comprised of a dose escalation phase to determine the MTD or maximum administered dose (MAD), and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of NB003.
The dose escalation phase will enroll patients with advanced gastrointestinal stromal tumor (GIST) who have progressed on or had an intolerability to imatinib and other standard of cares (SoCs) or refused other SoCs, and patients with advanced malignancies other than GIST that harbors KIT or PDGFRα gene alterations who have relapsed or have refractory disease without an available effective therapy. The number of patients to be enrolled during the dose escalation part will vary depending on the underlining dose-toxicity curve and the number of dose levels tested prior to reaching MTD or MAD. After the MTD or MAD has been determined, based on emerging safety/PK data, one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s) to establish the RP2D for dose expansion phase. This step will be regarded as RP2D confirmation part of dose escalation phase.
In the dose expansion phase, additional patients will be enrolled to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα. Dose expansion phase is planned to investigate NB003 at the RP2D determined from dose escalation phase.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 258 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies |
| Actual Study Start Date : | August 6, 2021 |
| Estimated Primary Completion Date : | July 31, 2025 |
| Estimated Study Completion Date : | December 31, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dose Escalation Phase and Dose Expansion Phase
Dose escalation cohort: NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met. RP2D: one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s) Dose expansion phase: In the dose expansion phase, additional patients will be enrolled at RP2D to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα. |
Drug: NB003 tablets
NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met. |
- Incidence of dose-limiting toxicities [ Time Frame: Approximately 24 months since the escalation first subject enrolled ]Dose Escalation Phase：Dose-limiting toxicities will be reviewed as a subset of adverse events that occur within the first 28 days of dosing and meet protocol-specified criteria.
- Incidence of adverse events [ Time Frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled ]Dose Escalation Phase and Dose Expansion Phase: An AE is any untoward medical occurrence in a participant who received study drug without regard to causal relationship.
- Objective Response Rate (ORR) [ Time Frame: Approximately 26 months since the Expansion first subject enrolled ]Dose Expansion Phase: Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)
- Duration of Response(DOR) [ Time Frame: Approximately 26 months since the Expansion first subject enrolled. ]Dose Expansion Phase: DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.
- Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t) [ Time Frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled ]Dose Escalation Phase and Dose Expansion Phase: AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.
- Maximum observed plasma concentration (Cmax) [ Time Frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled ]Dose Escalation Phase and Dose Expansion Phase: Maximum observed plasma concentration (Cmax)
- Time to Cmax (Tmax) [ Time Frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled ]Dose Escalation Phase and Dose Expansion Phase: Time to Cmax (Tmax)
- Terminal elimination half life [ Time Frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled ]Dose Escalation Phase and Dose Expansion Phase: Terminal elimination half life
- Objective Response Rate (ORR) [ Time Frame: Approximately 24 months since the escalation first subject enrolled ]Dose Escalation Phase: Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)
- Duration of Response(DOR) [ Time Frame: Approximately 24 months since the escalation first subject enrolled ]Dose Escalation Phase: DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.
- Cancer relevant gene mutations [ Time Frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled ]Dose Escalation Phase and Dose Expansion Phase:Cancer relevant gene mutations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males or females of any race ≥18 years age.
-
Histologically-confirmed diagnosis of unresectable, relapsed or metastatic GIST or other advanced malignancies.
-
For dose escalation phase:
- GIST patients must have progressed on or had an intolerability to imatinib and other SoCs or refused other SoCs.
- Patients with an advanced solid tumor other than GIST must have relapsed or had refractory disease without an available effective therapy and harbor KIT or PDGFRα gene alterations (central laboratory confirmation is not required for screening).
- For dose expansion phase:
Cohort 1: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to at least imatinib, sunitinib, regorafenib and ripretinib (≥ fifth line therapy setting); Cohort 2a: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib and sunitinib, and who have not received additional systemic therapy for advanced GIST (third line therapy setting); Cohort 2b: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib, sunitinib and regorafenib, and who have not received additional systemic therapy for advanced GIST (forth line therapy setting); Cohort 3: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib and have not received additional systemic therapy for advanced GIST (second line therapy setting); Cohort 4: GIST patients with PDGFRα exon 18 mutation and must have progressed on or been intolerant to avapritinib; in the countries/regions where avapritinib is not SoC, avapritinib-naïve patients can be enrolled; Cohort 5: Unresectable or metastatic melanoma patients with demonstrated evidence for KIT gene mutation and/or amplification, must have progressed on or been intolerant to SoCs; Cohort 6: Patients with other advanced malignancies other than GIST or melanoma which must be relapsed or refractory without an available effective therapy and harbor KIT or PDGFRα gene alterations.
-
- For dose expansion phase: at least one measurable lesion per RECIST v1.1/mRECIST.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 12 weeks.
- Adequate organ and marrow function.
- Tumor sample collection is required.
Exclusion Criteria:
- Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum wash-out period of 21 days prior to the initiation of study drug administration.
- Major surgery within 4 weeks of the first dose.
- Radiotherapy with a limited field of radiation for palliation within 1 week prior to the first dose, with the exception as defined.
- Patients currently receiving medications or herbal supplements known to be strong inhibitors or inducers of CYP3A4.
- Patients currently receiving acid-reducing agents and are unable to stop use at least 2 weeks prior to the first dose.
- Any known active central nervous system metastases and/or carcinomatous meningitis. Active infection including hepatitis B, hepatitis C, and HIV.
- Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, uncontrolled pericardial effusion, uncontrolled pleural effusion, or any other conditions, which in the judgment of Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
- Any evidence of severe or uncontrolled systemic diseases which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04936178
| Contact: Lanjiao Wu | +86 13761453966 | TMF-ISF@newbaypharma.com | |
| Contact: Yanhua Xu | +86 13916714882 | TMF-ISF@newbaypharma.com |
Show 34 study locations
| Responsible Party: | Ningbo Newbay Technology Development Co., Ltd |
| ClinicalTrials.gov Identifier: | NCT04936178 |
| Other Study ID Numbers: |
NB003-01 |
| First Posted: | June 23, 2021 Key Record Dates |
| Last Update Posted: | May 15, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Neoplasms |